Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Clinical trial NCT06467357 · RECRUITING

Trial details

NCT number: NCT06467357
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Biliary Tract Cancer

Start date: 2024-08-12
Primary completion: 2028-06-12
Enrollment: 620

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.